Form 4: aTyr Pharma Director Paul Schimmel Increases Stake in Company

Director Paul Schimmel reports acquiring additional shares of aTyr Pharma (ATYR) through a series of transactions, increasing his indirect holdings.

Summary

• Paul Schimmel, a director at aTyr Pharma, has reported several transactions involving the company's common stock.
• On July 22, 2024, he indirectly acquired 41,052 shares at a weighted average price of $1.7417 per share.
• On July 23, 2024, he indirectly acquired 6,648 shares at a weighted average price of $1.8163 per share.
• On July 24, 2024, he indirectly acquired 52,300 shares at a weighted average price of $1.9319 per share.
• He also disposed of 8,890 shares of common stock.
• Following these transactions, Schimmel indirectly owns 413,023 shares through Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel and 679,143 shares through Schimmel Revocable Trust U/A Dtd 9/6/2000.
• The reporting person will provide full information regarding the number of shares purchased at each separate price upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The acquisitions could be seen as slightly positive, but the disposal offsets this.

Positives

• The director's purchase of shares could be interpreted as a positive signal about his confidence in the company's future prospects.

Negatives

• The disposal of 8,890 shares could be interpreted as a negative signal.

Risks

• The document does not explicitly mention any risks.
• However, insider trading activity can sometimes be a sign of underlying issues within a company, so it warrants monitoring.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into a company's performance and future prospects. Form 4 filings are a routine part of this monitoring process.

Stakeholder Impact

• The increased stake of a director may increase investor confidence.

Key Dates